about
Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathwayInhibitory signalling to the Arp2/3 complex steers cell migrationVandetanib as a potential new treatment for estrogen receptor-negative breast cancers.Control of MT1-MMP transport by atypical PKC during breast-cancer progression.Arpin downregulation in breast cancer is associated with poor prognosis.Similar NF-κB gene signatures in TNF-α treated human endothelial cells and breast tumor biopsies.NF-kappa B genes have a major role in inflammatory breast cancerVasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalingsIdentification of 5 novel genes methylated in breast and other epithelial cancers.Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patientsmicroRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenograftsPIK3R1 underexpression is an independent prognostic marker in breast cancer.Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues.Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy.A Molecular Predictor Reassesses Classification of Human Grade II/III GliomasTubulin glycylases are required for primary cilia, control of cell proliferation and tumor development in colon.SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patientsDifferential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells.Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data.MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients.MDA-MB-231 breast cancer cells overexpressing single VEGF isoforms display distinct colonisation characteristics.Identification of new candidate therapeutic target genes in triple-negative breast cancerPIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancerPrognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer.Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas.ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathwaysUnraveling the Role of Huntingtin in Breast Cancer Metastasis.Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity.CAG repeat size in Huntingtin alleles is associated with cancer prognosis.Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome.CXC chemokines located in the 4q21 region are up-regulated in breast cancer.High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors.High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism.miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness.Cell death and neuronal differentiation of glioblastoma stem-like cells induced by neurogenic transcription factors.
P50
Q21135589-B8AC56E1-6952-4530-A2EF-A8F7224A35B1Q24338480-CA06F3AD-1546-4C7B-8F78-04366B889C86Q27853297-C5E9EE2D-26DC-40CB-ADCB-DE109DFE508EQ30577989-3C346838-6F4A-44D3-A63F-B5291A65028EQ30724719-2052B739-AD40-4EB9-B627-0D15A7B0D86FQ31022986-1A0E02A6-8A79-4935-A3E9-ED0A9E32C77EQ33318125-02D67941-E424-4499-8E31-D275837B673AQ33557623-2CAD7E86-F134-45F2-8E8F-03BD53056169Q33737079-5893E5D2-5076-460F-A75B-CC21541B6BA6Q33919243-5819CA22-EFEC-48BC-9E56-17617ADD0E62Q34312916-23BECE87-65C5-4236-AA15-6D917F66E3D8Q34465302-D2DBBCE7-D5DE-43D5-BC96-5BD0A130B4DAQ34478129-7C0A3256-4140-46E7-BE31-DFB7D515412FQ34663619-2866D0F9-6F10-4BBE-B02A-F65EB430AF70Q34677690-A19DB8C8-374F-4B42-8DF0-07852AD2C941Q34785423-CEE5AB2E-BDD0-44A3-9C62-8CA0EA7B890BQ34806540-EE62953F-7A68-44DA-96FF-1F0AA56B2A82Q34855870-6FA812B9-F2A6-45B0-B94A-6D5C5BBF29A2Q34998421-096121AF-2AA0-4C07-AAAC-220030867B4CQ35214798-2B883041-75C6-4C4B-912E-3EF0C72CE31AQ35567227-1398D737-A02F-464A-B04E-9EB12A8433AAQ35682549-97D8EF7C-C9E7-48EF-B484-3039B5B66F0AQ35735341-889E68A3-BBAB-41F8-B375-09F2CD620D87Q36027061-3FFF9587-311C-48B8-A170-D1162BB90F81Q36153325-0314A593-4D2F-415B-B3B9-33C4FEC8F1F4Q36393206-0BC2C685-6E8F-419E-9FA4-30514D2A2523Q36750699-D6043A0C-384B-49E0-84EB-B34267055A32Q37174025-420469C3-6AA8-4A7D-814A-33BF4E4BCEFEQ37565157-DF9F711B-0C22-483F-AD12-8F6FBB530CD8Q37687387-49E294AE-079E-446A-9265-606CF71625BCQ37708965-5C1D1874-CBBA-447B-8638-DF8702E7443DQ38842190-0A1F406A-5680-4667-BB31-9A741F7C09C6Q39583752-F2F56D8D-5944-4C14-BC9F-89A85297F690Q39918359-56EEFE66-C1A6-489E-A2D4-2988BC94F552Q44542715-0D0B4EA5-CC10-405A-B30E-F85F5F48830FQ46876505-578DE66E-753C-433F-BC64-B6825006629BQ46968614-58E628C4-5E4C-469B-9011-CBF95064C055Q47213795-7AFE752A-85F9-490F-8AF4-85D8A0C6A6F1Q48111857-020DF5A4-E566-41E3-9BCF-337694E31216Q48344044-EDE3A417-8F13-4468-96F3-9C5E40757EE0
P50
name
Sophie Vacher
@en
type
label
Sophie Vacher
@en
prefLabel
Sophie Vacher
@en